ESC 365 - Residual diabetic risk: from glucose lowering to cardiovascular protection.

ESC Professional Premium Access

Residual diabetic risk: from glucose lowering to cardiovascular protection.

Session: How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options

Topic: Cardiovascular Pharmacotherapy

Speaker: Professor N. Marx (Aachen, DE)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Nikolaus Marx

RWTH University Hospital Aachen, Aachen (Germany)

52 presentations

13 followers

4 more presentations in this session

Residual risk in dyslipidaemias: from statins to PCSK9 inhibitors and beyond.

Speaker: Professor E. Stroes (Amsterdam, NL)

Residual inflammatory risk.

Speaker: Professor W. Koenig (Munich, DE)

Residual thrombotic risk: from monotherapy to dual pathway inhibition.

Speaker: Professor B. Rocca (Casamassima, IT)

How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options – discussion.

Access the full session

How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options

Speakers: Professor N. Marx, Professor E. Stroes, Professor W. Koenig, Professor B. Rocca

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources